At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 154 enrolled
Drug / intervention
Deucravacitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP)
In Brief
A Phase 4 clinical trial evaluating Deucravacitinib and Placebo for Psoriasis. Completed, enrolled 154 participants across 29 sites in 5 countries.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesFrance, Germany, Poland, United Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedJul 2022
Enrollment StartOct 2022
Primary CompletionJan 2024
Study CompletionOct 2024
TodayJul 2026
First PostedJul 28, 2022
Enrollment StartOct 6, 2022
Primary CompletionJan 11, 2024
Study CompletionOct 17, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.9 years ago
Interventions
Deucravacitinibdrug
Specified dose on specified days
Placeboother
Specified dose on specified days